SBIR-STTR Award

Cancer Therapy Through Redirecting Natural Antibodies
Award last edited on: 12/30/2023

Sponsored Program
STTR
Awarding Agency
NIH : NCI
Total Award Amount
$99,863
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Moo J Cho

Company Information

SangStat Medical Corporation

6300 Dumbarton Circle
Fremont, CA 94555
   (510) 789-4300
   N/A
   www.sangstat.com

Research Institution

University of North Carolina

Phase I

Contract Number: 1R41CA074768-01A1
Start Date: 3/3/1998    Completed: 2/28/1999
Phase I year
1998
Phase I Amount
$99,863
Human and Old World primates naturally produce a large amount of antibodies which recognize an epitope Gal alpha 1-->3Gal. The present proposal is to test if the antibodies can be directed to folate receptor-expressing cancerous cells by means of a small MW targeting ligand that consists of the disaccharide and folic acid, referred to as FGG conjugate. When delivered to the target cell, the antibodies are expected to cause cell death by either complement-mediated lysis or antibody-dependent cell-mediated cytotoxicity. The concept feasibility will be tested specifically for treating ovarian cancer as the ultimate goal. It is known that the ovarian epithelial carcinoma cells overexpress the folate receptor. After the FGG receptor conjugate is synthesized, this study will first establish the specificity of binding of the FGG conjugate to the cell surface receptor as well as the antiGal antibodies, followed by elucidation of cytotoxic mechanism. For this series of experiments, folate, receptor-expressing IGROV1 cells derived from human ovarian cancer will be used. Since the FGG conjugate will be eventually administered intraperitoneally, it is imperative to map the immunological profile of the peritoneal fluid from the cancer patients. Finally the study will demonstrate that IGROV1 cells are killed in the peritoneal fluid in the presence of the FGG conjugate.

Thesaurus Terms:
folate, immunoconjugate, neoplasm /cancer immunotherapy, ovary neoplasm, vitamin receptor cell mediated cytotoxicity, ligand, monoclonal antibody, neoplastic cell cell line

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----